ATE347606T1 - Gentherapie für kongestives herzversagen - Google Patents

Gentherapie für kongestives herzversagen

Info

Publication number
ATE347606T1
ATE347606T1 AT97940830T AT97940830T ATE347606T1 AT E347606 T1 ATE347606 T1 AT E347606T1 AT 97940830 T AT97940830 T AT 97940830T AT 97940830 T AT97940830 T AT 97940830T AT E347606 T1 ATE347606 T1 AT E347606T1
Authority
AT
Austria
Prior art keywords
heart failure
congestive heart
gene therapy
present
myocardium
Prior art date
Application number
AT97940830T
Other languages
English (en)
Inventor
H Kirk Hammond
Paul A Insel
Peipei Ping
Steven R Post
Meihua Gao
Original Assignee
Univ California
Collateral Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California, Collateral Therapeutics filed Critical Univ California
Application granted granted Critical
Publication of ATE347606T1 publication Critical patent/ATE347606T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1787—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
AT97940830T 1996-09-05 1997-09-05 Gentherapie für kongestives herzversagen ATE347606T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70866196A 1996-09-05 1996-09-05
US4893397P 1997-06-16 1997-06-16

Publications (1)

Publication Number Publication Date
ATE347606T1 true ATE347606T1 (de) 2006-12-15

Family

ID=26726691

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97940830T ATE347606T1 (de) 1996-09-05 1997-09-05 Gentherapie für kongestives herzversagen

Country Status (9)

Country Link
EP (1) EP0934422B1 (de)
JP (1) JP2002514908A (de)
CN (1) CN1234835A (de)
AT (1) ATE347606T1 (de)
AU (1) AU741931B2 (de)
CA (1) CA2262406C (de)
DE (1) DE69737062T2 (de)
EA (1) EA199900261A1 (de)
WO (1) WO1998010085A2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA001616B1 (ru) 1995-02-28 2001-06-25 Зе Риджентс Оф Зи Юнивесити Оф Кэлифоньэ Способ лечения болезни сердца, способ лечения недостаточности периферических сосудов и способ ограничения доставки и экспрессии трансгенной конструкции в определенном органе или структуре
DE69733815T2 (de) 1996-02-15 2006-06-08 Biosense Webster, Inc., Diamond Bar Sonde zur exkavation
US6443974B1 (en) 1996-07-28 2002-09-03 Biosense, Inc. Electromagnetic cardiac biostimulation
US6465237B1 (en) 1997-07-01 2002-10-15 Millennium Pharmaceuticals, Inc. Cloning and characterization of a human adenylyl cyclase
WO1999001547A1 (en) * 1997-07-01 1999-01-14 Cor Therapeutics, Inc. Cloning and characterization of a human adenylyl cyclase
ES2255155T3 (es) 1998-02-05 2006-06-16 Biosense Webster, Inc. Dispositivo para la administracion intracardiaca de farmacos.
EP1085910A2 (de) * 1998-05-30 2001-03-28 Collateral Therapeutics, Inc. Methoden zur veränderung des phänotyps von herzzellen
IT1308613B1 (it) 1999-02-17 2002-01-09 Pharmacia & Upjohn Spa Acidi grassi essenziali nella prevenzione di eventi cardiovascolari.
EP1255822A2 (de) 1999-12-27 2002-11-13 The Regents Of The University Of California Modifizierte adenylylcyclase vom typ vi für gentheraphie bei congestiven herzkrankheiten
ITMI20010129A1 (it) * 2001-01-25 2002-07-25 Pharmacia & Upjohn Spa Acidi grassi essenziali nella terapia di insufficienza cardiaca e scompenso cardiaco
US20070265221A1 (en) * 2006-05-09 2007-11-15 Weiss Robert G Methods to improve creatine kinase metabolism and contractile function in cardiac muscle for the treatment of heart failure
WO2009065080A1 (en) * 2007-11-16 2009-05-22 San Diego State University Research Foundation Compositions and method for manipulating pim-1 activity in circulatory system cells
WO2009105135A1 (en) 2008-02-19 2009-08-27 Celladon Corporation Compositions for enhanced uptake of viral vectors in the myocardium

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5334521A (en) * 1991-11-18 1994-08-02 American Cyanamid Company Cloning and characterization of a cardiac adenylyl cyclase
US6034071A (en) * 1994-09-16 2000-03-07 Iyengar; Srinivas Ravi V. Mutant activated GS α and adenylyl cyclase 2 for use as therapeutic agents
WO1997016169A1 (en) * 1995-11-01 1997-05-09 Chiron Corporation Treatment of a cardiovascular indication by delivery of therapeutics to the pericardial space
JP2000500017A (ja) * 1995-11-17 2000-01-11 ウォルフガンク−エム フランツ 遺伝子治療核酸構造体、その製造と心臓疾患治療へのその利用

Also Published As

Publication number Publication date
CA2262406A1 (en) 1998-03-12
EA199900261A1 (ru) 1999-10-28
EP0934422A2 (de) 1999-08-11
EP0934422B1 (de) 2006-12-06
WO1998010085A3 (en) 1998-05-14
DE69737062T2 (de) 2007-07-12
CN1234835A (zh) 1999-11-10
JP2002514908A (ja) 2002-05-21
WO1998010085A2 (en) 1998-03-12
AU741931B2 (en) 2001-12-13
DE69737062D1 (de) 2007-01-18
CA2262406C (en) 2010-12-07
AU4251997A (en) 1998-03-26

Similar Documents

Publication Publication Date Title
DE69737062D1 (de) Gentherapie für kongestives herzversagen
DE69534669D1 (de) Nukleinsaeure enthaltende zusammensetzungen, herstellung und verwendung
ATE160178T1 (de) Verfahren und diagnostische kits unter verwendung von säuger-stresspromotoren zur bestimmung der toxizität einer verbindung
IL88208A0 (en) Acylated uridine and cytidine and uses thereof
WO1999040197A3 (en) Variants of the angiogenic factor vascular endothelial cell growth factor: vegf
EP1180040A4 (de) Methoden zur behandlung von kongestivem herzversagen
DE69929810D1 (de) Verwendung von tetracyclinderivaten zur steigerung der interleukin-10 produktion
EA200000926A1 (ru) Экспрессия генов биосинтеза трегалозы в растениях
DK1019082T3 (da) Fremgangsmåde til moduleringen af neovaskularisering og/eller væksten af kollaterale arterier og/eller andre arterier fra forudeksisterende arteriolære forbindelser
NO971341L (no) Promoter for reseptor tyrosinkinase TIE
EP0770089A4 (de) Wachstumsdifferenzierungsfaktor-12
EA200100583A1 (ru) Композиции, содержащие лактадгерин или его варианты, и способы их использования
WO2001048164A3 (en) Modified adenylylcyclase type vi useful in gene therapy for congestive heart failure
DK0655926T3 (da) Ny sonde til tumordiagnose eller tumorterapi
DE3767287D1 (de) Potenzierung von prazosin.
FI864597A0 (fi) Kardiotoniska tiazoloner.
DE69529750D1 (de) Verbesserungen in der herstellung von proteinen in wirtszellen
ATE236250T1 (de) Antisense-sequenzen für die hemmung der expression des adhäsionsmoleküls icam-1
EA199700243A1 (ru) Производное аминотетралина для лечения сердечно-сосудистых заболеваний
DE69929683D1 (de) Antisense modulierung von lfa-3
ATE79615T1 (de) Cardiotonische phenyloxazolone.
WO1999031136A3 (en) Methods for maintaining or restoring tissue-appropriate phenotype of soft tissue cells
PT925064E (pt) 5-androsteno-3beta,17alfa-diol como um inibidor do crescimento tumoral
DE60028750D1 (de) Verwendung von tagatose zur verbesserung wichtiger blutfaktoren
ATE389014T1 (de) Phosphorylierte glyoxalase i und deren verwendung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties